載入中
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
前收盤價
US$1.19
−US$0.06 · -4.80%
盤後
US$1.20
+US$0.01 · +0.84%
10月12日 下午7:49 ET
盤中時間採用ET。市場資料可能有所延遲。
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
日內區間
目前US$1.19
52週區間
目前US$1.19
盤中時間採用ET。市場資料可能有所延遲。
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
日內區間
目前US$1.19
52週區間
目前US$1.19
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 42.4萬 USD | — | 35.7萬 USD | — | — |
| 毛利 | −42.4萬 USD | — | −35.7萬 USD | — | — |
| 研究與開發 | 1812.6萬 USD | 1574.5萬 USD | 1696.8萬 USD | 1416.9萬 USD | 1100.2萬 USD |
| 銷售、一般及管理費用 | 943萬 USD | 893.2萬 USD | 999.7萬 USD | 537.2萬 USD | 232.1萬 USD |
| 營業費用 | 2713.2萬 USD | 2467.7萬 USD | 2660.8萬 USD | 2124.1萬 USD | 1332.3萬 USD |
| 折舊和攤銷 | 42.4萬 USD | 40萬 USD | 35.7萬 USD | 38.1萬 USD | 34.5萬 USD |
| 營業利益 | −2755.6萬 USD | −2467.7萬 USD | −2696.5萬 USD | −2124.1萬 USD | −1332.3萬 USD |
| 淨利 | −2660.9萬 USD | −2348.6萬 USD | −2565.2萬 USD | −1388.9萬 USD | −1277.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年8月19日 | 1:3 | — | — |
股票分割 | 2020年1月6日 | 1:8 | — | — |
已生效 2022年8月19日
1:3
已生效 2020年1月6日
1:8
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
